AstraZeneca said that the European Medicines Agency has recommended the approval of Forxiga, its vaccine for symptomatic heart failure, and Trixeo Aerosphere for treating adult patients with slight to serious chronic obstructive pulmonary disease.

The UK-based pharmaceutical group said its diabetes treatment Forxiga received the Committee for Medicinal Products for Human Use recommendation based on results from the DAPA-HF third stage tests.

Whereas in the case of Trixeo Aerosphere, which is a triple-combination regimen, the CHMP recommendation supposedly followed the outcome of the ETHOS advance phase test backed by data from the KRONOS third stage trial. Trixeo Aerosphere is already approved in the U.S., China and Japan for patients with chronic obstructive pulmonary disease.

If approved, AstraZeneca said that Forxiga would become the first SGLT2 inhibitor administered for heart failure with minimal ejection fraction in patients with and without type-2 diabetes. Heart failure is a life-threatening disease in which the heart fails to distribute enough blood in the body, affecting 15 million people in Europe.

Both test programs for Trixeo Aeropshere included more than 15,500 subjects around the world enrolled in 11 clinical trials. Forxiga's trials consist of 35 tests with close to 35,000 participants.

Known as "smoker's lung", the serious chronic obstructive pulmonary disease is a potentially fatal condition that affects over 380 million people globally and is mainly caused by excessive smoking. COPD is also caused by occupational hazards like chemical fumes and air pollution.

In a related development, U.S. President Donald Trump plans to secure a deal with AstraZeneca for a COVID vaccine before Britain does, the Mirror reported.

The company said that supplies will be shipped out in a first-come, first-served arrangement. Trump has promised Americans that he will distribute 300 million doses by early 2021 under his $10-billion Operation Warp Speed program.

AstraZeneca's representative confirmed that "if the U.S. Food and Drug Administration clears it first, they will get it first," the Mirror report added.